Abstract
This chapter discusses a heterogeneous group of pediatric diseases in the oral cavity, maxilla, and mandible that can be diagnosed based on combined features of their appearances on examination, clinical laboratory test results, radiology in bone lesions when appropriate, histology, immunopathology, and molecular abnormalities. These pathological analyses serve to distinguish these diseases as reactive, congenital, inflammatory, benign, or malignant.
While some entities are unique to the oral cavity, many also occur elsewhere in the body. Knowledge of their existence in the oral cavity or jaws is thus key to their diagnosis.
Readers will find the presentation and definition of these lesions and disease conditions in an atlas-like format informative. An accompanying detailed text that describes the clinical–pathological correlations will also facilitate the establishment of an accurate diagnosis.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Agnihotri S, Jalali S, Wilson MR, et al. The genetic landscape of schwannoma. Nat Genet. 2016;48:1339–48.
Niimura M. Neurofibromatosis. Rinsho Derma. 1973;15:653–63.
Jacoby LB, Jones D, Davis K, et al. Molecular analysis of the NF2 tumor-suppressor gene in schwannomatosis. Am J Hum Genet. 1997;61:1293–302.
Antinheimo J, Sankila R, Carpen O, et al. Population-based analysis of sporadic and type 2 neurofibromatosis-associated meningiomas and schwannomas. Neurology. 2000;54:71–6.
MacCollin M, Chiocca EA, Evans DG, et al. Diagnostic criteria for schwannomatosis. Neurology. 2005;64:1838–45.
MacCollin M, Woodfin W, Kronn D, et al. Schwannomatosis: a clinical and pathologic study. Neurology. 1996;46:1072–9.
Baser ME, Friedman JM, Evans DG. Increasing the specificity of diagnostic criteria for schwannomatosis. Neurology. 2006;66:730–2.
Smith MJ, Kulkarni A, Rustad C, et al. Vestibular schwannomas occur in schwannomatosis and should not be considered an exclusion criterion for clinical diagnosis. Am J Med Genet A. 2012;158A:215–9.
Plotkin SR, Blakeley JO, Evans DG, et al. Update from the 2011 International Schwannomatosis Workshop: from genetics to diagnostic criteria. Am J Med Genet A. 2013;161A:405–16.
Hulsebos TJ, Plomp AS, Wolterman RA, et al. Germline mutation of INI1/SMARCB1 in familial schwannomatosis. Am J Hum Genet. 2007;80:805–10.
Sestini R, Bacci C, Provenzano A, et al. Evidence of a four-hit mechanism involving SMARCB1 and NF2 in schwannomatosis- associated schwannomas. Hum Mutat. 2008;29:227–31.
Hadfield KD, Newman WG, Bowers NL, et al. Molecular characterisation of SMARCB1 and NF2 in familial and sporadic schwannomatosis. J Med Genet. 2008;45:332–9.
Piotrowski A, Xie J, Liu YF, et al. Germline loss-of-function mutations in LZTR1 predispose to an inherited disorder of multiple schwannomas. Nat Genet. 2014;46:182–7.
Paganini I, Chang VY, Capone GL, et al. Expanding the mutational spectrum of LZTR1 in schwannomatosis. Eur J Hum Genet. 2015;23:963–8.
Smith MJ, Isidor B, Beetz C, et al. Mutations in LZTR1 add to the complex heterogeneity of schwannomatosis. Neurology. 2015;84:141–7.
DeBella K, Szudek J, Friedman JM. Use of the national institutes of health criteria for diagnosis of neurofibromatosis 1 in children. Pediatrics. 2000;105(3 Pt 1):608–14.
Williams VC, Lucas J, Babcock MA, et al. Neurofibromatosis type 1 revisited. Pediatrics. 2009;123(1):124–33.
Huson SM, Hughes RAC. The neurofibromatoses: a pathogenetic and clinical overview. London: Churchill Livingstone; 1994.
Evans DG. Neurofibromatosis type 2 (NF2): a clinical and molecular review. Orphanet J Rare Dis. 2009;4:16.
Asthagiri AR, Parry DM, Butman JA, et al. Neurofibromatosis type 2. Lancet. 2009;373:1974–86.
Evans DG. Neurofibromatosis 2 [Bilateral acoustic neurofibromatosis, central neurofibromatosis, NF2, neurofibromatosis type II]. Genet Med. 2009;11:599–610.
Evans DG, Huson SM, Donnai D, et al. A genetic study of type 2 neurofibromatosis in the United Kingdom. I. Prevalence, mutation rate, fitness, and confirmation of maternal transmission effect on severity. J Med Genet. 1992;29:841–6.
Evans DG, Huson SM, Donnai D, et al. A genetic study of type 2 neurofibromatosis in the United Kingdom. II. Guidelines for genetic counselling. J Med Genet. 1992;29:847–52.
Parry DM, Eldridge R, Kaiser-Kupfer MI, et al. Neurofibromatosis type 2 (NF2): clinical characteristics of 63 affected individuals and clinical evidence for heterogeneity. Am J Med Genet. 1994;52:450–61.
Mautner VF, Baser ME, Takkar SD, et al. Vestibular schwannoma growth in patients with neurofibromatosis type 2: a longitudinal study. J Neurosurg. 2002;96:223–8.
Ragge NK, Baser ME, Klein J, et al. Ocular abnormalities in neurofibromatosis 2. Am J Ophthalmol. 1995;120:634–41.
Mautner VF, Lindenau M, Baser ME, et al. Skin abnormalities in neurofibromatosis type 2. Arch Dermatol. 1997;133:1539–43.
Gardner WJ, Frazier CH. Hereditary bilateral acoustic tumors. J Hered. 1933;22:7–8.
Gardner WJ, Turner O. Bilateral acoustic neurofibromas: further clinical and pathologic data on hereditary deafness and Recklinghausen’s disease. Arch Neurol Psychiatry. 1940;44:76–99.
Ruggieri M. The different forms of neurofibromatosis. Childs Nerv Syst. 1999;15:295–308.
Wishart JH. Case of tumours in the skull, dura mater, and brain. Edinburgh Med Surg J. 1822;18:393–7.
Mautner VF, Tatagiba M, Guthoff R, et al. Neurofibromatosis type 2 in the paediatric age group. Neurosurgery. 1993;33:92–6.
MacCollin M, Bove C, Kluwe L, et al. The natural history of neurofibromatosis 2 in 31 affected children. Ann Neurol. 1998;44(3):A576.
MacCollin M, Mautner VF. The diagnosis and management of neurofibromatosis type 2 in childhood. Semin Pediatr Neurol. 1998;5:243–52.
Ruggieri M, Gabriele AL, Polizzi A, et al. Natural history of neurofibromatosis type 2 with onset before the age of 1 year. Neurogenetics. 2013;14:89–98.
Trofatter JA, MacCollin MM, Rutter JL, et al. A novel moesin-, ezrin-, radixin-like gene is a candidate for the neurofibromatosis 2 tumor suppressor. Cell. 1993;72:791–800.
MacCollin M, Ramesh V, Jacoby LB, et al. Mutational analysis of patients with neurofibromatosis 2. Am J Hum Genet. 1994;55:314–20.
Kluwe L, Mautner VF. A missense mutation in the NF2 gene results in moderate and mild clinical phenotypes of neurofibromatosis type 2. Hum Genet. 1996;97:224–7.
Kluwe L, Mautner VF. Mosaicism in sporadic neurofibromatosis 2 patients. Hum Mol Genet. 1998;7:2051–5.
Donofrio V, Passeretti U, Russo S. Neurothekeoma of the thumb: a case report. Tumori. 1988;74:751–4.
Rosati L, Fratamico FC, Eusebi V. Cellular neurothekeoma. Appl Pathol. 1986;4:186–91.
King DT, Barr RJ. Bizarre cutaneous neurofibromas. J Cutan Pathol. 1980;7:21–31.
Gmyrek RF, Beer R, Silvers DN. Periungual myxoid neurofibroma. Cutis. 2002;69:54–6.
Eckardt A, Swennen G, Teltzrow T. Melanotic neuroectodermal tumor of infancy involving the mandible: 7-year follow-up after hemimandibulectomy and costochondral graft reconstruction. J Craniofac Surg. 2001;12:349–54.
Barrett AW, Morgan M, Ramsay AD, et al. A clinicopathologic and immunohistochemical analysis of melanotic neuroectodermal tumor of infancy. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2002;93:688–98.
Agarwal P, Saxena S, Kumar S, et al. Melanotic neuroectodermal tumor of infancy: presentation of a case affecting the maxilla. J Oral Maxillofac Pathol. 2010;14:29–32.
Madrid C, Aziza J, Hlali A, et al. Melanotic neuroectodermal tumour of infancy: a case report and review of the aetiopathogenic hypotheses. Med Oral Patol Oral Cir Bucal. 2010;15:e739–42.
Gupta A, Trehan A, Marwaha RK, et al. Melanotic neuroectodermal tumour in an infant. Indian J Paediatr. 2002;69:725–6.
Neven J, Hulsbergen-van der Kaa C, Groot-Loonen J, et al. Recurrent melanotic neuroectodermal tumor of infancy: a proposal for treatment protocol with surgery and adjuvant chemotherapy. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2008;106:493–6.
Kruse-Losler B, Gaertner C, Burger H, et al. Melanotic neuroectodermal tumor of infancy: systematic review of the literature and presentation of a case. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2006;102:204–16.
Krompecher E. Zur Histogenese und Morphologie der Adamantinome und sostinger Kiefergeschwϋlste. Beitr Path Anat. 1918;64:165–97.
Borello ED, Gorlin RJ. Melanotic neuroectodermal tumor of infancy: a neoplasm of neural crest origin. Report of a case associated with high urinary excretion of vanilmandelic acid. Cancer. 1966;19:196–206.
Lips CJM, Lentjes EGWM, Hoppene HWM, et al. Familial paragangliomas. Hered Cancer Clin Pract. 2006;4:169–76.
Tekautz TM, Pratt CB, Jenkins JJ, et al. Pediatric extraadrenal paraganglioma. J Pediatr Surg. 2003;38:1317–21.
Dent TL, Thompson NW, Fry WJ. Carotid body tumors. Surgery. 1976;80:365–72.
Dickinson PH, Griffin SM, Guy AJ, et al. Carotid body tumour: 30 years experience. Br J Surg. 1986;73:14–6.
Fanning JR, Woods FM, Christian HJ. Metastatic carotid body tumor. Report of the case with the review of literature. JAMA. 1963;185:49–50.
Patetsios P, Gable DR, Garrett WV, et al. Management of carotid body paragangliomas and review of a 30 years experience. Ann Vasc Surg. 2002;16:331–8.
Crona J, Taieb D, Pacak K. New perspectives on pheochromocytoma and paraganglioma: toward a molecular classification. Endocr Rev. 2017;38(6):489–515.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2021 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Sikhar, V., Hawkins, C.E., Hazrati, LN. (2021). Pediatric Surgical Pathology of Head and Neck Tumors of the Peripheral Nerve and Paraganglionic System. In: Campisi, P., Forte, V., Ngan, BY., Taylor, G. (eds) Pediatric Head and Neck Textbook. Springer, Cham. https://doi.org/10.1007/978-3-030-59265-3_21
Download citation
DOI: https://doi.org/10.1007/978-3-030-59265-3_21
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-59263-9
Online ISBN: 978-3-030-59265-3
eBook Packages: MedicineMedicine (R0)